[go: up one dir, main page]

WO2025057126A1 - Dérivé hétérocyclique en tant qu'activateur de sting (stimulateur des gènes de l'interféron) et composition pharmaceutique le comprenant - Google Patents

Dérivé hétérocyclique en tant qu'activateur de sting (stimulateur des gènes de l'interféron) et composition pharmaceutique le comprenant Download PDF

Info

Publication number
WO2025057126A1
WO2025057126A1 PCT/IB2024/058923 IB2024058923W WO2025057126A1 WO 2025057126 A1 WO2025057126 A1 WO 2025057126A1 IB 2024058923 W IB2024058923 W IB 2024058923W WO 2025057126 A1 WO2025057126 A1 WO 2025057126A1
Authority
WO
WIPO (PCT)
Prior art keywords
ethyl
methyl
carbamoyl
pyrazole
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2024/058923
Other languages
English (en)
Korean (ko)
Inventor
이수민
손태익
하해찬
김유로
황경림
유종석
김석규
김소희
정능금
이원제
박수진
문형우
권호석
이재웅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samjin Pharmaceutical Co Ltd
Original Assignee
Samjin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samjin Pharmaceutical Co Ltd filed Critical Samjin Pharmaceutical Co Ltd
Publication of WO2025057126A1 publication Critical patent/WO2025057126A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Definitions

  • Compounds that can activate STING could increase immune responses by linking anti-tumor innate immunity with adaptive immunity. , and can convert cold tumors into hot tumors, and can produce synergistic effects by using immune checkpoint inhibitors together.
  • the present invention provides a heterocyclic derivative compound as a STING activator, a tautomer thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
  • the present invention provides a compound as a STING activator, a tautomer thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
  • the present invention provides a pharmaceutical composition for preventing or treating a disease in which STING activity modulation is beneficial, comprising the compound as a STING activator, the tautomer thereof, the stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method for preventing or treating a disease in which STING activity modulation is beneficial, comprising a step of administering to a subject a compound as a STING activator, the tautomer thereof, the stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.
  • the present invention provides the use of a compound, a tautomer thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof as a STING activator for the prevention or treatment of a disease in which modulation of STING activity is beneficial.
  • the present invention provides the use of a compound, a tautomer thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof as a STING activator in the manufacture of a medicament for the prevention or treatment of a disease in which modulation of STING activity is beneficial.
  • a kit for the manufacture of a medicament for the prevention or treatment of a disease in which modulation of STING activity is beneficial.
  • a compound as a STING activator, a tautomer thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof The present invention provides a compound according to any one of the following (1) to (8), a tautomer thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
  • Y is N or CRa, wherein Ra is H, C1-C6 alkyl or C1-C6 alkoxy,
  • Ri, R 2 , R 4 and R 5 are each independently H or C1-C6 alkyl, Rs and R6 are each independently H or NH2, but at least one of R3 and R6
  • L is - (Cl- C6 alkylene)-, -0-, -0-CC1-C6 alkylene)-, -NR b - or - NRb- (Cl- C6 alkylene)-, wherein Rb is H or C1-C6 alkyl,
  • Y is N or CR a
  • Ra is H, C1-C6 alkyl or C1-C6 alkoxy
  • Ri, R 2 , R 4 and R 5 are each independently H or C1-C6 alkyl
  • Rs and R6 are each independently H or NH2, and at least one of R3 and R6 is W,
  • L is -(Cl- C6 alkylene)-, -0-, -0-CC1-C6 alkylene)-, -NR b - or - NRr(Cl- C6 alkylene)-, and Rb is H or C1-C6 alkyl,
  • Y is N or CRa, wherein R a is C1-C6 alkoxy
  • Ri, R 2 , R 4 and R5 are each independently C1-C6 alkyl
  • Methanesulfonyl chloride (MsCl , 1.2 eq) and TEA (1.5 eq) were added, and the mixture was stirred at room temperature for 15 hours. After confirming the completion of the reaction, distilled water was added, and the organic layer was extracted using CH2CI2. The moisture remaining in the organic layer was completely removed with anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure and used without purification.
  • Methanesulfonyl chloride (MsCl , 1.2 eq) and TEA (1.5 eq) were added, and the mixture was stirred at room temperature for 2 hours. After confirming the completion of the reaction, distilled water was added, and the organic layer was extracted using CH 2 C1 2. The moisture remaining in the organic layer was completely removed with anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure and used without purification.
  • Step B (E)- 3- (4- ((2- (3- (8-oxa- 2-azaspiro [4.5] decan-2-yl ) propoxy )- 4-carbamoyl- 6-nitrophenyl) amino) but- 2-en- 1-yl )- 2- ( 1-ethyl- 3-methyl- 1H-pyrazole- 5 -carboxamido)- 3H-imidazo [4 , 5- b ] pyridine- 6 -carboxamide ( ( ⁇ )- 3— (4— ( (2— (3— (8— oxa— 2— azasp iro [4.5] decan-2-y 1 ) pr opoxy ) — 4— car bamoy 1 — 6— nitr opheny 1 ) am i no ) but — 2— en— 1-yl )-2-( 1-ethyl -3-methyl- lH-pyr azole-5- carboxamido) -3H- i mi dazo
  • Stimulation of the donor bead releases singlet oxygen, which initiates a chain of energy transfer reactions at the acceptor bead, emitting strong light at 615 nm.
  • Binding of the compound to human STING R232 is indicated by decreased binding of the competitive biotinylated ligand, producing a low 615 nm signal.
  • the reduction in competitive binding by the compounds was calculated by taking the measured value of the vehicle control (DMS0) as 100%, and the IC 50 values were determined by fitting the inhibition curves using a four parameter variable slope model in GraphPad Pr i sm® software. The determined IC 50 values are presented in Table 3 below.
  • the binding of the compound stabilizes the protein structure, resulting in an increase in the melting temperature (Tm), and the ATm was calculated by subtracting the Tm of the control group (DMSO) from the Tm of the test group.
  • Tm melting temperature
  • DMSO control group
  • THP-1 dual KI-hSTING-R232 cells (catalog number thpd-r232), in which the wild-type hSTING-R232 gene was introduced into THP-1 dual KO-STING cells, were purchased from Invivogen and maintained in growth medium consisting of RPMI 1640, 2 mM L-glutamine, 25 mM HEPES, 10% heat-inactivated fetal bovine serum (FBS), 100 units/ml penicillin, 100 ug/ml streptomycin, and 100 ug/ml nomocin.
  • Experimental Example 3-2 IRF3-luciferase assay Intracellular STING activation was evaluated through the activity of IRF3, a transcription factor of the STING signaling pathway.
  • THP-1 Dual KI-hSTING-R232 cells were resuspended in test medium at a density of 5 x 10 5 cells/ml, and 180 uL of cells were seeded into each well of a 96-well clear plate. 20 uL of the compound or vehicle (DMSO) was added to each well, and incubated for 20 hours at 37 °C, 5% CO 2 . To assess the expression of the IRF3-luciferase reporter, 20 uL per well was transferred to a 96-well white plate, and 50 uL of QUANTI-luc (Invivogen) detection reagent was added to each well, and luminescence was read using a Tecan Spark microplate reader (Tecan).
  • DMSO compound or vehicle
  • the EC 5 o values of the compounds were expressed as the luminescence under vehicle (DMSO) treatment. Fold change values for the response were obtained and plotted as a function of compound concentration in GraphPad Prism® software and fitted using a four-parameter variable slope model to determine the EC 5 o values. The determined EC 5 o values are shown in Table 5 below.
  • NF-KB-SEAP reporter 20 uL per well was transferred to a 96-well clear plate, 180 uL QUANTI-Blue (Invivogen) detection reagent was added to each well, and incubated at 37 °C, 5% CO 2 for 3 hours. Absorbance at 655 nm was measured using a Tecan Spark microplate reader (Tecan). EC 5 o values of the compounds were determined by plotting them as a function of compound concentration in GraphPad Prism® software and fitting them using a four-parameter variable slope model. The determined EC 5 o values are presented in Table 6 below.
  • HCT116-DualTM cells (catalog number: hctd-nfis) expressing a luciferase gene encoding secreted luciferase under the control of the ISG54 minimal promoter together with five IFN-stimulated response elements, the activity of which can be monitored to study the interferon regulatory factor (IRF) pathway, were purchased from Invivogen and maintained in growth medium consisting of DMEM, 4.5 g/l glucose, 2 mM L-glutamine, 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 100 Ig/ml streptomycin, 100 ug/ml nomosin, 10 ug/ml blasticidin, and 100 ug/ml zeocin.
  • DMEM fetal bovine serum
  • FBS heat-inactivated fetal bovine serum
  • HCT-116 dual cells were seeded in test medium at a density of 5 x 104 cells/ml. The cells were resuspended in 10 ⁇ L of the medium and 180 ⁇ L of cells were seeded into each well of a 96-well clear plate. 20 ⁇ L of the compound or vehicle (DMSO) was added to each well and incubated at 37 °C, 5% CO 2 for 18 to 24 hours.
  • DMSO compound or vehicle

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un dérivé hétérocyclique utile en tant qu'activateur de STING, un tautomère de celui-ci, un stéréoisomère de celui-ci ou un sel pharmaceutiquement acceptable de celui-ci, une composition pharmaceutique le comprenant, un procédé faisant appel à celui-ci pour prévenir ou traiter des maladies sur lesquelles la régulation de l'activité de STING a un effet bénéfique, et leurs utilisations.
PCT/IB2024/058923 2023-09-15 2024-09-13 Dérivé hétérocyclique en tant qu'activateur de sting (stimulateur des gènes de l'interféron) et composition pharmaceutique le comprenant Pending WO2025057126A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20230123504 2023-09-15
KR10-2023-0123504 2023-09-15

Publications (1)

Publication Number Publication Date
WO2025057126A1 true WO2025057126A1 (fr) 2025-03-20

Family

ID=95020998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/058923 Pending WO2025057126A1 (fr) 2023-09-15 2024-09-13 Dérivé hétérocyclique en tant qu'activateur de sting (stimulateur des gènes de l'interféron) et composition pharmaceutique le comprenant

Country Status (2)

Country Link
KR (1) KR20250040871A (fr)
WO (1) WO2025057126A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180105514A1 (en) * 2016-04-07 2018-04-19 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2019134705A1 (fr) * 2018-01-08 2019-07-11 成都先导药物开发股份有限公司 Immunomodulateur
WO2020132582A1 (fr) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Agonistes de sting et leurs utilisations
US20220267364A1 (en) * 2019-07-25 2022-08-25 Shanghai Jemincare Pharmaceuticals Co., Ltd. Heterocyclic amide compound, preparation method therefor and use thereof
WO2022246597A1 (fr) * 2021-05-24 2022-12-01 Forever Millets Limited Dérivés d'imidazopyridine en tant qu'agonistes de sting

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180105514A1 (en) * 2016-04-07 2018-04-19 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2019134705A1 (fr) * 2018-01-08 2019-07-11 成都先导药物开发股份有限公司 Immunomodulateur
WO2020132582A1 (fr) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Agonistes de sting et leurs utilisations
US20220267364A1 (en) * 2019-07-25 2022-08-25 Shanghai Jemincare Pharmaceuticals Co., Ltd. Heterocyclic amide compound, preparation method therefor and use thereof
WO2022246597A1 (fr) * 2021-05-24 2022-12-01 Forever Millets Limited Dérivés d'imidazopyridine en tant qu'agonistes de sting

Also Published As

Publication number Publication date
KR20250040871A (ko) 2025-03-25

Similar Documents

Publication Publication Date Title
AU2019264475B2 (en) Bcl-2 inhibitors
JP7716110B2 (ja) ピリミジン－４（３ｈ）－オンヘテロ環式化合物、その調製方法、およびその医薬的使用
AU2019262927B2 (en) Pyridazinones as PARP7 inhibitors
AU2011256380B2 (en) Macrocyclic compounds as Trk kinase inhibitors
CA2627839C (fr) Derives pyrrolo-[2,1-f]-[1,2,4]-triazin-4-ylamines inhibiteurs de la igf-1r kinase pour le traitement des cancers et autres maladies hyperproliferatives
RU2622104C2 (ru) Макроциклические ингибиторы киназы lrrk2
CN103732583B (zh) Trpv4拮抗剂
CN111153901A (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
CA3189912A1 (fr) Composes bicycliques, compositions et utilisation de ceux-ci
KR20220061958A (ko) Cd38의 억제제로서의 헤테로바이사이클릭 아미드
TW202102509A (zh) 靶向prmt5之化合物
AU2016360481A1 (en) Novel biphenyl compound or salt thereof
JP2010523522A (ja) Ｊａｋ３阻害剤としてのピロロピリミジン誘導体
CA2897333A1 (fr) Composes de thiazolecarboxamide et de pyridinecarboxamide utiles comme inhibiteurs de kinases pim
TW202208379A (zh) 新穎的巨環lrrk2激酶抑制劑
AU2014307437A1 (en) Novel fused pyrimidine compound or salt thereof
KR20170090424A (ko) 호흡기 세포융합 바이러스 （ｒｓｖ）의 복제에 대하여 저해 활성을 갖는 피페리딘 치환된 피라졸로［１，５―ａ］피리미딘 유도체
JP7625141B2 (ja) Ｅｒｂｂ２の阻害剤としての縮合四環キナゾリン誘導体
CN115867346B (zh) 激酶抑制剂
AU2018320021A1 (en) Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof
US20230027198A1 (en) Inhibitors of enl/af9 yeats
WO2022140769A1 (fr) Dérivés de pyrimidine à fusion hétéroaryle lactame servant d'inhibiteurs d'erbb2
KR20240148322A (ko) 이작용성 아릴설폰아미드 화합물
WO2024229121A1 (fr) Composés pour le traitement du cancer
CN115873000B (zh) 异喹啉酮类及喹唑啉酮类化合物及其组合物和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24864857

Country of ref document: EP

Kind code of ref document: A1